<DOC>
	<DOCNO>NCT00002822</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug way kill tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Randomized phase III trial compare effect two combination chemotherapy regimens follow radiation therapy treat patient small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Radiation Therapy Patients With Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival rate patient newly diagnose small cell lung cancer good performance status treat intensive regimen ifosfamide/carboplatin/etoposide mid-cycle vincristine ( VICE ) vs. standard chemotherapy follow , feasible , thoracic radiotherapy . - Compare adverse effect treatment quality life ( include psychological distress , physical status , functional status global quality life ) patient . - Compare Rotterdam Symptom Checklist vs. EORTC QLQ-C30 LC13 quality-of-life questionnaire relation compliance ability detect difference treatment . OUTLINE : This randomize study . The first group receive standard combination chemotherapy doxorubicin/cyclophosphamide/etoposide ( ACE ) cisplatin/etoposide ( PE ) every 3 week 6 course . The second group receive intensive combination chemotherapy carboplatin/ifosfamide/etoposide day 1-3 vincristine day 14 ( VICE ) . Courses repeat every 4 week 6 course . Patients group consider thoracic radiotherapy begin 4-5 week first day last course chemotherapy . Concurrent prophylactic antibiotic give . Patients relapse may receive treatment clinician 's option . Patients follow monthly 6 month , every 2 month 1 year , every 3 month 2 year , every 6 month 5 year , annually thereafter . PROJECTED ACCRUAL : A total 400 patient enter 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Microscopically proven small cell lung cancer Diagnosis base bronchial , mediastinal , pleural , lung , lymph node biopsy , sputum cytology , bronchial brushing fine needle aspirate cytology No pleural fluid cytology No prior therapy PATIENT CHARACTERISTICS : Age : Any age Performance status : WHO 02 Hematopoietic : WBC 3,000 ANC 1,500 Platelets 100,000 Hepatic/Renal : Alkaline phosphatase , aminotransferase , sodium , LDH normal 1 abnormal Creatinine urea normal Creatinine clearance GFR 65 mL/min Other : No clinical evidence infection No prior concurrent malignancy interfere protocol treatment comparisons No condition contraindicate treatment Willing able complete qualityoflife questionnaire Hospital Anxiety Depression Scale , Rotterdam Symptom Checklist , EORTC questionnaires complete prior randomization PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2000</verification_date>
	<keyword>limited stage small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>